Endometrium is one of the main factors in pregnancy. During assisted reproductive
technology (ART) treatments, some cycles are cancelled due to inadequate
endometrial growth. This study was conducted to evaluate the effectiveness of
platelet-rich plasma (PRP) in the treatment of thin endometrium. Ten patients
with history of inadequate endometrial growth in frozen-thawed embryo transfer
(FET) cycles were recruited into the study. Intrauterine infusion of PRP was
performed. Endometrial thickness was assessed. Chemical and clinical pregnancies
were reported. In all patients, endometrial thickness increased after PRP and
embryo transfer was done in all of them. Five patients were pregnant. According
to this study, it seems that PRP was effective for endometrial growth in patient
with thin endometrium.
Background:Repeated implantation failure (RIF) is a major challenge in reproductive medicine and despite several methods that have been described for management, there is little consensus on the most effective one.Objective:This study was conducted to evaluate the effectiveness of platelet-rich plasma in improvement of pregnancy rate in RIF patients.Materials and Methods:Twenty women with a history of RIF who were candidates for frozen-thawed embryo transfer were recruited in this study. Intrauterine infusion of 0.5 ml of platelet-rich plasma that contained platelet 4-5 times more than peripheral blood sample was performed 48 hrs before blastocyst transfer. Results:Eighteen participants were pregnant with one early miscarriage and one molar pregnancy. Sixteen clinical pregnancies were recorded and their pregnancies are ongoing.Conclusion:According to this study, it seems that platelet-rich plasma is effective in improvement of pregnancy outcome in RIF patients.
Background: Adequate endometrial growth is principal for implantation and pregnancy. Thin endometrium is associated with lower pregnancy rate in assisted reproductive technology. Some frozen-thawed embryo transfer cycles are cancelled due to inadequate endometrial growth.
Objective: To assess the effectiveness of autologous platelet-rich plasma (PRP) intrauterine infusion for the treatment of thin endometrium.
Materials and Methods: A total of 72 patients who had a history of cancelled frozen-thawed embryo transfer cycle due to the thin endometrium (< 7mm) were assessed for the eligibility to enter the study between 2016 and 2017. Twelve patients were excluded for different reasons, and 60 included patients were randomly assigned to PRP or sham-catheter groups in a double-blind manner. Hormone replacement therapy was administered for endometrial preparation in all participants. PRP intrauterine infusion or sham-catheter was performed on day 11-12 due to the thin endometrium and it was repeated after 48 hr if necessary.
Results: Endometrial thickness increased at 48 hr after the first intervention in both groups. All participants needed second intervention due to an inadequate endometrial expansion. After second intervention, endometrial thickness was 7.21 ± 0.18 and 5.76 ± 0.97 mm in the PRP group and sham-catheter group, respectively. There was a significant difference between the two groups. (p < 0.001). Embryo transfer was done for all patients in PRP group and just in six cases in the sham-catheter group. Chemical pregnancy was reported in twelve cases in the PRP group and two cases in the sham-catheter group.
Conclusion: According to this trial, PRP was effective in endometrial expansion in patients with refractory thin endometrium.
Pre-emptive use of gabapentin 600 mg orally, significantly decreases postoperative pain and PONV, and also rescues analgesic and anti emetic drug requirements in patients who undergo abdominal hysterectomy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.